10 results
8-K
EX-99.1
IMPLQ
Impel Pharmaceuticals Inc
12 May 23
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
8:03am
and Development (R&D) Expenses: R&D expenses were $3.0 million for Q1 2023, compared with $3.7 million for Q1 2022. The decrease is primarily due to lower … personnel costs and program costs as the Company redirected its resources from R&D activities and pivoted its focus to supporting commercial
8-K
EX-99.1
IMPLQ
Impel Pharmaceuticals Inc
14 Nov 22
Impel PHARMACEUTICALS Announces THIRD Quarter 2022 Financial Results and Provides CORPORATE Update
7:55am
, there were $0.1 million in revenues for the same period of 2021.
Research and Development (R&D) Expenses: R&D expenses were $3.2 million for the third quarter … 2022 compared with $5.9 million for the same period of 2021. The decrease in R&D spending was primarily due to a reduction in Trudhesa clinical
8-K
EX-99.1
IMPLQ
Impel Pharmaceuticals Inc
15 Aug 22
Impel PHARMACEUTICALS Announces SECOND Quarter 2022 Financial Results and Provides CORPORATE Update
8:06am
(R&D) Expenses: R&D expenses were $4.0 million for the second quarter 2022 compared with $6.1 million for the same period of 2021. The decrease in R … &D spending was primarily due to reduction in Trudhesa clinical expenses as the Phase 3 STOP 301 study was closed, partially offset by an increase
8-K
EX-99.1
IMPLQ
Impel Pharmaceuticals Inc
16 May 22
Impel PHARMACEUTICALS Announces first Quarter 2022 Financial Results and Provides CORPORATE Update
8:23am
and Development (R&D) Expenses: R&D expenses were $3.7 million for the first quarter 2022 compared with $4.3 million for the same periods of 2021. The decrease … in R&D spending was primarily due to the reduction in Trudhesa clinical expenses as the Phase 3 study was concluded.
Selling, General
8-K
EX-99.1
IMPLQ
Impel Pharmaceuticals Inc
14 Apr 22
Regulation FD Disclosure
8:30am
initiated in late September 2021 ahead of the October commercial launch Research and Development (R&D) expenses $4.5M for 4th quarter 2021 vs. $8.8M
8-K
EX-99.1
p3z03kxf9
24 Mar 22
Impel NeuroPharma Announces FOURTH Quarter AND fULL YEAR 2021 Financial Results and Provides CORPORATE Update
8:27am
8-K
EX-99.1
1vx0qs5 pp4
18 Jan 22
Impel NeuroPharma Provides Updates on TrudhesaTM Launch
8:01am
8-K
EX-99.1
4sftqkcmny158kkfx2ij
15 Nov 21
Impel NeuroPharma Announces THIRD Quarter 2021 Financial Results and Provides CORPORATE Update
8:04am
8-K
EX-99.1
99wmqb
16 Aug 21
Impel NeuroPharma Announces SECOND Quarter 2021 Financial Results and Provides CORPORATE Update
7:59am
8-K
EX-99.1
ygdslubjhrvv
7 Jun 21
Impel NeuroPharma Announces First Quarter 2021 Financial Results and Provides Business Update
8:00am
- Prev
- 1
- Next